Publications & ASH Poster Presenters

Recent + Selected

Recent Selected Publications

Hoang-Minh LB, Dutra-Clarke M, Breunig JJ, Sarkisian MR. Glioma cell proliferation is enhanced in the presence of tumor-derived cilia vesicles. Cilia. 2018 PMID:30410731 | PMCID:PMC6219037

Alexander N, Marrano P, Thorner P, Naranjo A, Van Ryn C, Martinez D, Batra V, Zhang L, Irwin MS, Baruchel S. Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma. J Pediatr Hematol Oncol. 2018 PMID:30334904

Harding K, Bergman N, Smith A, Lindley S, Szivek A, Milner R, Brawner W, Lejeune A. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma. Vet Comp Oncol. 2018 PMID:30117260

Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, Mohan R, Mikhaeel NG, Kirova Y, Specht L, Yahalom J. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018 PMID:30108066

Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, […] Gururangan S, […] et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 PMID:29741745 | PMCID:PMC6176802

Gay LA, Turner PC, Renne R. Contemporary Ribonomics Methods for Viral microRNA Target Analysis. Noncoding RNA. 2018 PMID:30424002

Murphy KT, Hossain MI, Swiderski K, Chee A, Naim T, Trieu J, Haynes V, Read SJ, Stapleton DI, Judge SM, Trevino JG, Judge AR, Lynch GS. Mas receptor activation slows tumor growth and attenuates muscle wasting in cancer. Cancer Res. 2018 PMID:30420474

Journy N, Indelicato DJ, Withrow DR, Akimoto T, Alapetite C, Araya M, Chang A, Chang JH, Chon B, Confer ME, Demizu Y, Dendale R, Doyen J, Ermoian R, Gurtner K, Hill-Kayser C, Iwata H, Kim JY, Kwok Y, Laack NN, Lee C, Lim DH, et al. Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. Radiother Oncol. 2018 PMID:30414759

Eskander A, Blakaj DM, Dziegielewski PT. Decision making in advanced larynx cancer: An evidenced based review. Oral Oncol. 2018 PMID:30409301

Bargal SA, Rafiee R, Crews KR, Wu H, Cao X, Rubnitz JE, Ribeiro RC, Downing JR, Pounds SB, Lamba JK. Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML. Oncotarget. 2018 PMID:30405880 | PMCID:PMC6201857

Aries IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 PMID:30404791

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, et al. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 PMID:30396912

Pearlstein KA, Wang K, Amdur RJ, Shen CJ, Dagan R, Weiss J, Grilley-Olson JE, Zanation A, Hackman TG, Thorp B, Blumberg JM, Patel S, Sheets N, Weissler MC, Mendenhall WM, Chera BS. Quality of Life for Patients with Favorable Risk HPV-Associated Oropharyngeal Cancer After De-Intensified Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2018 PMID:30395903

Gentile D, Markham MJ, Eaton T. Patients With Cancer and Social Media: Harness Benefits, Avoid Drawbacks. J Oncol Pract. 2018 PMID:30383479

Tay J, Vij R, Norkin M, Buadi F, Kindwall-Keller TL, Roberts JS, White DJ, Wood RP, Blanthorn-Hazell SE, Rossi AC, Dhanasiri S, Zafar F, Newhouse K, McCurdy AR. Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. Leuk Lymphoma. 2018 PMID:30380358

Adjei IM, Temples MN, Brown SB, Sharma B. Targeted Nanomedicine to Treat Bone Metastasis. Pharmaceutics. 2018 PMID:30366428

FitzGerald TJ, Bishop-Jodoin M, Laurie F, O’Meara E, Davis C, Bogart J, Kalapurakal J, Siegel MJ, Chakravarthy B, Okunieff P, Haffty B, Michalski J, Ulin K, Followill DS, Kry S, Knopp M, Zhang J, Rosen D, Rosen M, Xiao Y, Schwartz L, Moni J, et al. The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols. Int J Radiat Oncol Biol Phys. 2018 PMID:30353882

Bullard WL, Flemington EK, Renne R, Tibbetts SA. Connivance, Complicity, or Collusion? The Role of Noncoding RNAs in Promoting Gammaherpesvirus Tumorigenesis. Trends Cancer. 2018 PMID:30352676

Parker PA, Banerjee SC, Matasar MJ, Bylund CL, Rogers M, Franco K, Schofield E, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane D. Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: a cluster randomized controlled trial. Cancer. 2018 PMID:30335188

Niglio de Figueiredo M, Krippeit L, Ihorst G, Sattel H, Bylund CL, Joos A, Bengel J, Lahmann C, Fritzsche K, Wuensch A. ComOn-Coaching: The effect of a varied number of coaching sessions on transfer into clinical practice following communication skills training in oncology: Results of a randomized controlled trial. PLoS One. 2018 PMID:30289905 | PMCID:PMC6173449

Bates JE, Bradley JA. To Treat or Not to Treat? A Postmastectomy Question. Int J Radiat Oncol Biol Phys. 2018 PMID:30191860

Kharfan-Dabaja MA, Reljic T, Murthy HS, Ayala E, Kumar A. Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2018 PMID:30145196

Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 PMID:30138085

Wang L, Li P, Xiao X, Li J, Li J, Yang HH, Tan W. Generating lung-metastatic osteosarcoma targeting aptamers for in vivo and clinical tissue imaging. Talanta. 2018 PMID:30029428

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, […] Wingard JR, […] et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 PMID:29907552

Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018 PMID:29733389

Holtzman AL, Williams JP, Hutchinson DF, Morris CG, Yeung AR. Improving Patient-reported Pain During Radiotherapy Through Nurse Involvement and Patient Education. Am J Clin Oncol. 2018 PMID:29215379

Mokhtech M, Morris CG, Indelicato DJ, Rutenberg MS, Amdur RJ. Patterns of Failure in Patients With Adult Medulloblastoma Presenting Without Extraneural Metastasis. Am J Clin Oncol. 2018 PMID:29045264

Zarrinpar A, Faltermeier CM, Agopian VG, Naini BV, Harlander-Locke MP, Kaldas FM, Farmer DG, Busuttil RW. Metabolic Factors Affecting Hepatocellular Carcinoma in Steatohepatitis. Liver Int. 2018 PMID:30427105

Yang R, Li SW, Chen Z, Zhou X, Ni W, Fu DA, Lu J, Kaye FJ, Wu L. Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer. J Natl Cancer Inst. 2018 PMID:30423141

Noennig B, Bozorgmehri S, Terry R, Otto B, Su LM, Crispen PL. Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract. Bladder Cancer. 2018 PMID:30417049 | PMCID:PMC6218108

Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK. ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. Eur J Med Chem. 2019 PMID:30384048

Muller HL, Merks JHM, Geoerger B, Grill J, Hargrave D, Glade Bender J, Gururangan S, Navid F, Johnston M, Bachir J, Elze MC, FÃ¼rst-Recktenwald S. Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab. Pediatr Blood Cancer. 2018 PMID:30378286

Fields DP, Roberts BM, Simon AK, Judge AR, Fuller DD, Mitchell GS. Cancer cachexia impairs neural respiratory drive in hypoxia but not hypercapnia. J Cachexia Sarcopenia Muscle. 2018 PMID:30362273

Wildes TJ, Flores CT, Mitchell DA. Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells. Stem Cells. 2018 PMID:30353618

Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV; MASCC Bone Study Group. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2018 PMID:30353228

Yang GS, Kumar S, Dorsey SG, Starkweather AR, Kelly DL, Lyon DE. Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors. Support Care Cancer. 2018 PMID:30343412

Wei J, Ma L, Li C, Pierson CR, Finlay JL, Lin J. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells. Curr Cancer Drug Targets. 2018 PMID:30332965

Maitra A, Sharma A, Brand RE, Van Den Eeden SK, Fisher WE, Hart PA, Hughes SJ, Mather KJ, Pandol SJ, Park WG, Feng Z, Serrano J, Rinaudo JAS, Srivastava S, Chari ST; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).. A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas. 2018 PMID:30325864

Yadav D, Park WG, Fogel EL, Li L, Chari ST, Feng Z, Fisher WE, Forsmark CE, Jeon CY, Habtezion A, Hart PA, Hughes SJ, Othman MO, Rinaudo JAS, Pandol SJ, Tirkes T, Serrano J, Srivastava S, Van Den Eeden SK, Whitcomb DC, Topazian M, Conwell DL; et al. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas. 2018 PMID:30325862

Fisher WE, Cruz-Monserrate Z, McElhany AL, Lesinski GB, Hart PA, Ghosh R, Van Buren G, Fishman DS, Rinaudo JAS, Serrano J, Srivastava S, Mace T, Topazian M, Feng Z, Yadav D, Pandol SJ, Hughes SJ, Liu RY, Lu E, Orr R, Whitcomb DC, Abouhamze AS, et al. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas. 2018 PMID:30325860 | PMCID:PMC6197069

Serrano J, Andersen DK, Forsmark CE, Pandol SJ, Feng Z, Srivastava S, Rinaudo JAS; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: From Concept to Reality. Pancreas. 2018 PMID:30325859 | PMCID:PMC6195329

Li D, Tian G, Wang J, Zhao LY, Co O, Underill ZC, Mymryk JS, Claessens F, Dehm SM, Daaka Y, Liao D. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival. Prostate. 2018 PMID:30009471

Williams SB, Shan Y, Jazzar U, Mehta HB, Baillargeon JG, Huo J, Senagore AJ, Orihuela E, Tyler DS, Swanson TA, Kamat AM. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. JAMA Surg. 2018 PMID:29955780

Garcia-Solano J, Turpin MC, Torres-Moreno D, Huertas-LÃ³pez F, Tuomisto A, Makinen MJ, Conesa A, Conesa-Zamora P. Two histologically colorectal carcinomas subsets from the serrated pathway show different methylome signatures and diagnostic biomarkers. Clin Epigenetics. 2018 PMID:30413173

Arroyo-Crespo JJ, Arminan A, Charbonnier D, Balzano-Nogueira L, Huertas-Lopez F, Marti C, Tarazona S, Forteza J, Conesa A, Vicent MJ. Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment. Biomaterials. 2018 PMID:30278346

Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, […] Norkin M, […] et al. nThe Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 PMID:30423481

Ren Y, Ay A, Gerke TA, Kahveci T. Identification of jointly correlated gene sets. J Bioinform Comput Biol. 2018 PMID:30419787

He Z, Gharaibeh RZ, Newsome RC, Pope JL, Dougherty MW, Tomkovich S, Pons B, Mirey G, Vignard J, Hendrixson DR, Jobin C. Campylobacterjejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut. 2018 PMID:30377189

O’steen L, Indelicato DJ. Advances in the management of craniopharyngioma. F1000Res. 2018 PMID:30363774 | PMCID:PMC6182675

Lin J, Chen L, Lin J, Wu H, Okunieff P, Wu B, Yang B, Chen J, Lin J, Zhang L. A novel approach for fast detection of sepsis with Gram-negative bacterial infection. Microb Biotechnol. 2018 PMID:30346117 | PMCID:PMC6196396

Lu J, Firpi-Morell RJ, Dang LH, Lai J, Liu X. An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection. Gastroenterology Res. 2018 PMID:30344812 | PMCID:PMC6188031

Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges. Gastroenterology. 2018 PMID:30342035

Flores CT, Wildes TJ, Drake JA, Moore GL, Dean BD, Abraham RS, Mitchell DA. Lin(-)CCR2(+) hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. Nat Commun. 2018 PMID:30333482 | PMCID:PMC6192988

Hoang-Minh LB, Siebzehnrubl FA, Yang C, Suzuki-Hatano S, Dajac K, Loche T, Andrews N, Schmoll Massari M, Patel J, Amin K, Vuong A, Jimenez-Pascual A, Kubilis P, Garrett TJ, Moneypenny C, Pacak CA, Huang J, Sayour EJ, Mitchell DA, Sarkisian MR, Reynolds BA, Deleyrolle LP. Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. EMBO J. 2018 PMID:30322894

Magdoom KN, Delgado F, BohÃ³rquez AC, Brown AC, Carney PR, Rinaldi C, Mareci TH, Ewing JR, Sarntinoranont M. Longitudinal evaluation of tumor microenvironment in rat focal brainstem glioma using diffusion and perfusion MRI. J Magn Reson Imaging. 2018 PMID:30318760

Çağlayan M, Wilson SH. Pol μ dGTP dGTP mismatch insertion opposite T coupled with ligation reveals promutagenic DNA repair intermediate. Nat Commun. 2018 PMID:30310068 | PMCID:PMC6181931

Yang Y, Zhu W, Feng L, Chao Y, Yi X, Dong Z, Yang K, Tan W, Liu Z, Chen M. G-Quadruplex-Based Nanoscale Coordination Polymers to Modulate Tumor Hypoxia and Achieve Nuclear-Targeted Drug Delivery for Enhanced Photodynamic Therapy. Nano Lett. 2018 PMID:30303384

Li L, Jiang Y, Cui C, Yang Y, Zhang P, Stewart K, Pan X, Li X, Yang L, Qiu L, Tan W. Modulating Aptamer Specificity with pH-Responsive DNA Bonds. J Am Chem Soc. 2018 PMID:30212189

Muhsen IN, Aljurf M, Wingard JR, Poland GA, Komanduri KV, Whitaker JA, Hashmi SK. Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. Vaccine. 2018 PMID:30195488

Brice DC, Toth Z, Diamond G. LL-37 disrupts the Kaposi’s sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells. Antiviral Res. 2018 PMID:30076864

Berg CJ, Fong GT, Thrasher JF, Cohen JE, Maziak W, Lando H, Drope J, Mejia R, Barnoya J, Nakkash R, Salloum RG, Parascandola M. The impact and relevance of tobacco control research in low-and middle-income countries globally and to the US. Addict Behav. 2018 PMID:30041132

Kim CH, Yeom YS, Nguyen TT, Han MC, Choi C, Lee H, Han H, Shin B, Lee JK, Kim HS, Zankl M, Petoussi-Henss N, Bolch WE, Lee C, Chung BS, Qiu R, Eckerman K. New mesh-type phantoms and their dosimetric applications, including emergencies. Ann ICRP. 2018 PMID:29651869

Laurent D, Oliveria SF, Shang M, Bova F, Freedman R, Rahman M. Techniques to Ensure Accurate Targeting for Delivery of Awake Laser Interstitial Thermotherapy. Oper Neurosurg (Hagerstown). 2018 PMID:29444286

Salloum RG, Louviere JJ, Getz KR, Islam F, Anshari D, Cho Y, O’Connor RJ, Hammond D, Thrasher JF. Evaluation of strategies to communicate harmful and potentially harmful constituent (HPHC) information through cigarette package inserts: a discrete choice experiment. Tob Control. 2018 PMID:28705893 | PMCID:PMC6156997

UF-Affiliated Posters at ASH 2018

1040 Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup
Program: Oral and Poster Abstracts Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I Hematology Disease Topics & Pathways: Anemias, Diseases, Technology and Procedures, Clinically relevant, genetic profiling
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
MaryRisinger, PhD1,2*, Vandy Black, MD, MSc3, Loan Hsieh, MD4*, Renee C. Prins, MD5*, Jill Menell, MD6*, Mohamad Badawi, MD7*, Cynthia Rutherford, MD8, Karen L. Bride, MD, PhD9, Omar Niss, MD2, Charles T. Quinn, MD2,10, Katie Giger Seu, PhD2*, Wenying Zhang, MD PhD11* and Theodosia A. Kalfa, MD, PhD2

1251 Bleeding and Thrombotic Risk in Low Dose Heparin Infusion As Compared to Standard Dose Heparin Infusion
Program: Oral and Poster Abstracts Session: 332. Antithrombotic Therapy: Poster I Hematology Disease Topics & Pathways: anticoagulant drugs, Non-Biological, Therapies, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Forat Lutfi, MD1, Rohit Boshnoi, MD2, Vikas Patel, MD3*, Aisha Alfasi4*, Michael Setteducato5*, Shuyao Zhang6*, Chintan Shah, MD7, Saji Kurian, PharmD4*, Chethana Kamath6*, Dae Jun Kim6* and Martina C. Murphy, MD8

1511 Sustained Fetal Hematopoiesis Contributes to Demise in Pediatric Myeloid Leukemia
Program: Oral and Poster Abstracts Session: 603. Oncogenes and Tumor Suppressors: Poster I Hematology Disease Topics & Pathways: Diseases, Biological Processes, MPN, Myeloid Malignancies, hematopoiesis
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Jingliao Zhang, MD1,2*, Nitza Vara, MS1*, Yan Yan, MD1*, Delli Robinson1*, Natalia Cristina Natalia1*, Shelly Y. Lensing1*, Xin Zhang, PhD3*, Youzhong Yuan, MD, PhD1*, Nicholas J Baltz1*, Daohong Zhou, MD3, Peter D. Emanuel, MD1 and Y. Lucy Liu, MD, PhD4

1367 CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias
Program: Oral and Poster Abstracts Session: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster I Hematology Disease Topics & Pathways:
Biological, multiple myeloma, Diseases, smoldering myeloma, Therapies, Biological Processes, Technology and Procedures, Plasma Cell Disorders, gene editing, Lymphoid Malignancies, NGS, pathogenesis
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Ryosuke Shirasaki, MD, PhD1,2*, Sara Gandolfi, MD1,2*, Ricardo De Matos Simoes, PhD1,2*, Geoffrey Matthews, PhD1,2*, Dennis Buckley1,2*, Olga Dashevsky, PhD1,2*, Sondra L. Downey-Kopyscinski, PhD1*, Huihui Tang, PhD1,2*, Michal Sheffer, PhD1,2*, Eugen Dhimolea, PhD1,2*, Brian Glassner, PhD2*, Megan Bariteau, BSc1,2*, Jeffrey Sorrell, BA1*, Johanna B Bruggenthies1*, Quinlan Sievers, BA3, Haley Poarch1*, Nicholas P Kwiatkowski, PhD4*, Tinghu Zhang, PhD4*, Jacob Laubach, MD5, Robert L. Schlossman, MD6, Paul Richardson1, Aedin Culhane, PhD7*, Richard WJ Groen, PhD8, Eric S. Fischer, PhD9*, Francisca Vazquez, Phd2*, Aviad Tsherniak, PhD2*, William C. Hahn, MD, PHD1,2*, Joan Levy10*, Daniel Auclair, PhD10*, Jonathan D. Licht, MD11, Jonathan J Keats, PhD12, Lawrence H. Boise, PhD 13,14, Benjamin L. Ebert, MD, PhD15, James Bradner, MD16, Nathanae Gray, PhD4* and Constantine S. Mitsiades, MD, PhD1,2

1407 Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
Program: Oral and Poster Abstracts Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Hematology Disease Topics & Pathways: Diseases, AML, Biological, Adult, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Farhad Ravandi, MBBS1, Camille N Abboud, MD2, Luke Paul Akard, MD3, Saar I. Gill, MD, PhD4, Jack W. Hsu, MD5*, Suman Kambhampati, MD6*, Irum Khan, MBBS7, Delong Liu, MD, PhD8, Wendy Stock, MD9, Janice W Brown, MD10, Asad Bashey, MD, PhD11, Gautam Borthakur, MD12, Courtney D. DiNardo, MD, MSc12, H. Kent Holland, MD11, Tapan M. Kadia, MD13, Hagop M. Kantarjian, MD13, Lawrence E Morris, MD11, Scott R Solomon, MD11, Richard David Mamelok, MD14*, Swapna Panuganti, Ph.D.14*, Rod Van Syoc14*, Alicia Wong, BS14*, Deborah Zimmerman, Ph.D.14*and Melhem Solh, MD11

1490 Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children’s Oncology Group Protocol AAML0531
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Hematology Disease Topics & Pathways: Diseases, AML, Pediatric, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , flow cytometry
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Laura Pardo1,2*, Lisa Eidenschink Brodersen, PhD1, Jatinder K Lamba, PhD3, Todd A Alonzo, PhD4,5*, Yi-Cheng Wang4*, Dana Paine6*, Alan S Gamis, MD, MPH7, E. Anders Kolb, MD8, Jessica A. Pollard, MD9,10, Todd M Cooper, DO11, Richard Aplenc, MD, PhD12, Soheil Meshinchi, MD, PhD4,13 and Michael R. Loken, PhD1*

1536 Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Hematology Disease Topics & Pathways: AML, Diseases, Non-Biological, Therapies, Pediatric, Biological Processes, chemotherapy, Study Population, Myeloid Malignancies, metabolomics
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Bradley Stockard, PharmD1, Huiyun Wu, PhD2*, Joy D. Guingab, PhD3*, Timothy J. Garrett, PhD3*, Jeffrey Rubnitz, MD, PhD4, Stanley Pounds, PhD2* and Jatinder K Lamba, PhD5

1538 WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Hematology Disease Topics & Pathways: Adult, AML, Diseases, Non-Biological, Therapies, Biological Processes, Technology and Procedures, Study Population, cytogenetics, epigenetics, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, immune mechanism, molecular testing, NGS, molecular interactions, WGS, signal transduction
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Brett M Stevens, PhD1, Amanda Winters, MD, PhD2, Taher Abbasi, MS, MBA3*, Neeraj Kumar Singh, B.Tech4*, Yashaswini S Ullal, B.E4*, Ilu Kumari, M.Sc.4*, Anuj Tyagi, M.Sc.4*, Aftab Alam, M.Sc.4*, Neelesh Lunkad, M.Tech4*, Leylah M. Drusbosky, PhD5, Christopher R. Cogle, MD6, Shireen Vali, PhD3* and Daniel A Pollyea, MD7

1539 Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Hematology Disease Topics & Pathways: AML, Diseases, Biological, Therapies, Non-Biological, Biological Processes, chemotherapy, Technology and Procedures, DNA repair, epigenetics, cytogenetics, genetic profiling, Myeloid Malignancies, genomics, TKI, newborn screening, NGS, molecular interactions, WGS, signal transduction
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Shireen Vali, PhD1*, Christopher R. Cogle, MD2, Neeraj Arora, MD3*, Krishnan Shekhar, Ph.D.3*, Mammen Chandy, MD3, Manju Sengar, MD, DM 4*, Hasmukh Jain, MD, DM4*, Girish Chinnaswamy, MD,
MRCP4*, Neeraj Kumar Singh, B.Tech5*, Shahabuddin Usmani, M.Sc.5*, Anusha Pampana, M.Sc.5*, Vijayashree P Shyamasundar, M.Sc.5*, Huzaifa Sikora, B.Tech5*, Ansu Kumar, M.Sc.5*, Taher Abbasi, MS, MBA1* and Vivek S Radhakrishnan, MD, DM, MSc3

1540 Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Hematology Disease Topics & Pathways: Diseases, AML, Biological, Therapies, Non-Biological, Biological Processes, Technology and Procedures, epigenetics, cytogenetics, Myeloid Malignancies, genomics, pharmacology, TKI, molecular testing, NGS, molecular interactions, WGS, signal transduction
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Jeffrey W. Tyner, PhD1, Brian J. Druker, MD2, Stephen E Kurtz, PhD3*, Cristina E. Tognon, PhD3*, Leylah M. Drusbosky, PhD4, Robinson Vidva, B.Tech5*, Yugandhara Narvekar, M.Sc.5*, Ashish Kumar Agrawal, B.V.Sc, A.H.5*, Saji Gera, M.Tech5*, Samiksha Avinash Prasad, M.Sc.5*, Vijayashree P Shyamasundar, M.Sc.5*, Gaurav Singh Tunwer, M.Sc.5*, Taher Abbasi, MS, MBA6*, Shireen Vali, PhD6* and Christopher R. Cogle, MD7

1541 Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, Biological Processes, Technology and Procedures, cytogenetics, genetic profiling, genomics, Myeloid Malignancies, TKI, molecular testing, NGS, molecular interactions, WGS, signal transduction
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Jeffrey W. Tyner, PhD1, Brian J. Druker, MD2, Cristina E. Tognon, PhD3*, Stephen E Kurtz, PhD3*, Leylah M. Drusbosky, PhD4, Diwyanshu Sahu, M.Sc.5*, Robinson Vidva, B.Tech5*, Shweta Kapoor, M.Sc.5*, Humera Azam, M.Sc.5*, Rajeev Kumar, B.Tech5*, Padmagiri G Chickdipatti, B.E5*, Nithya T Raveendaran,
M.Tech5*, Reshma P Gopi, M.Sc.5*, Taher Abbasi, MS, MBA6*, Shireen Vali, PhD6* and Christopher R. Cogle, MD7

2119 Microbiota Phylogenic Analysis Revealed Decreased Abundance of Faecalibacterium Prausnitzii, an Anti-Inflammatory Commensal Bacterium, in Patients with Chronic Graft-Versus-Host Disease
Program: Oral and Poster Abstracts Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I Hematology Disease Topics & Pathways: Adult, Biological Processes, Study Population, Clinically relevant, immune mechanism, inflammation

Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Nosha Farhadfar, MD1, Raad Z. Gharaibeh, PhD2*, John R. Wingard, MD1, Debra Lyon, PhD, RN, FAAN3*, Christian Jobin, PhD4*, Gary P Wang, MD, PhD5*, Michael Raymond Weaver, BA6*, Hemant S. Murthy, MD1 and Debra Lynch Kelly, PhD, RN, OCN, CNE3*

3509 The Association of Painful Crises with Patient Reported Outcomes in Sickle Cell Disease: The SHIP-HU Study
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster II Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Adult, Pediatric, Hemoglobinopathies, Study Population, Clinically relevant, Quality Improvement
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Donna k McClish, PhD1*, Wally R. Smith, MD2, Victoria Okhomiuna, MS, PHD2*, Daniel Sop Mouaffo, BS, MS3*, Richard Lottenberg, MD2,4, Ian Chen, MD2*, India Sisler, MD2*, Shirley Johnson, BA, LSW2*, Darla K Liles, MD5,6, Elizabeth Yang, MD, PhD7,8,9 and Thokozeni Lipato, MD10*

1967 The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data
Program: Oral and Poster Abstracts Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I Hematology Disease Topics & Pathways: Adult, apoptosis, multiple myeloma, Diseases, Non-Biological, Therapies, Biological Processes, chemotherapy, DNA repair, Study Population, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Ludek Pour, MD1*, Miquel Granell, MD2*, Roman Hajek, MD, PhD3, Albert Oriol, MD4*, Yvonne Efebera, MD5, Jacques Delaunay, MD6*, Katell Le Du, MD7*, Jean-Richard Eveillard, MD8*, Lionel Karlin, MD9*, Vladimir Maisnar, MD10*, Joaquin Martinez Lopez, MD11*, Maria-Victoria Mateos, MD, PhD12, Jan Moreb, MD13*, Vincent Ribrag, MD14, Paul Richardson15, Jan Straub, MD16*, Catriona Byrne, RN17, Christian Jacques, MD17, Hanan Zubair, MSc17* and Enrique Ocio, MD12*

1364 ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I Hematology Disease Topics & Pathways:
Diseases, AML, Therapies, Non-Biological, chemotherapy, Pediatric, Study Population, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Roya Rafiee, PhD1,2, Soheil Meshinchi, MD, PhD3 and Jatinder K Lamba, PhD4

2234 Pain Management in Hemophilia Α: Analysis of a Large US Insurance Claims Database
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster I Hematology Disease Topics & Pathways: Diseases, Hemophilia, Bleeding and clotting, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Mahek Garg1,2*, Karina Raimundo1*, Anisha Patel1* and Richard H Ko1
Sunday, December 2nd

2506 Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism
Program: Oral and Poster Abstracts Session: 331. Pathophysiology of Thrombosis: Poster II Hematology Disease Topics & Pathways: Adult, Diseases, Bleeding and clotting, Technology and Procedures, Thrombosis, Study Population, Clinically relevant, Thromboembolism, genetic profiling, Thrombotic Disorders, VTE, NGS, serologic tests, WGS
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Lauren Marsh Shevell, MD, MPH1, Eun-Ju Lee, MD2, Rahul Dhodapkar, MBBS3*, Daniel Dykas, BS, MBA4*, Andreea Popa, MD, PhD5*, Deqiong Ma, MD, PhD5*, Noffar Bar, MD5, Audrey Baluha, RN6*, Adrienne J. Burns, MMS, PA-C7*, Cassius Ilya Ochoa Chaar, MD5*, Anne Dupont, RN6*, Sean Gu, MD, PhD5*,Stephanie Halene, MD 8, Randy Luciano, MD, PhD5*, Rebecca Marien, RN6*, Natalia Neparidze, MD9, Terri L Parker, MD10, Xiaopan Yao, PhD5*, Rodney M. Camire, PhD11, Eduard Ebberink, PhD12*, Pablo Garcia de Frutos13*, Kavitha Gnanasambandan, PhD14*, Peter P. Sayeski, PhD14*, James A. Huntington, PhD15, Steven R. Lentz, MD, PhD16, Koen Mertens, PhD17*, Christopher Parish, PhD18*, Ray Rezaie, PhD19*, Jean M. Connors, BA, MD20, Andrew Leavitt, MD21, Allen Bale, MD3* and Alfred Ian Lee, MD, PhD22

2561 Cell Intrinsic and Extrinsic Mechanisms Mediate the Role of c-Myc Haploinsufficiency in Controlling HSC Fate
Program: Oral and Poster Abstracts Session: 501. Hematopoietic Stem and Progenitor Biology: Poster II Hematology Disease Topics & Pathways: Biological Processes, hematopoiesis
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Yue Sheng, PhD1,2, Chunjie Yu, Ph.D2,3*, Rui Ma, Master4* and Zhijian Qian, Ph.D2,3

1364 ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I Hematology Disease Topics & Pathways: Diseases, AML, Therapies, Non-Biological, chemotherapy, Pediatric, Study Population, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Roya Rafiee, PhD1,2, Soheil Meshinchi, MD, PhD3 and Jatinder K Lamba, PhD4

2696 Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia
Program: Oral and Poster Abstracts Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II Hematology Disease Topics & Pathways: Leukemia, ALL, Biological, Diseases, Adult, Therapies, CAR-Ts, Study Population, Lymphoid Malignancies, Clinically relevant, Quality Improvement
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Sanfang Tu, MD & PhD1*, Rui Huang, MD & PhD1*, Lan Deng, MD&PhD1*, Xuan Zhou, MD1*, Yanjie He, MD & PhD1*, Weijun Zhou, MD&PhD1*, Jilong Yang, MD1*, Chunyan Yue, MD1*, Anqin Wu1*, Meifang Li, MD&PhD1*, Zhenling Guo1*, Lung-Ji Chang, PhD2,3,4 and Yuhua Li, MD & PhD1

2698 DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-XL for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax
Program: Oral and Poster Abstracts Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II Hematology Disease Topics & Pathways: Diseases, Leukemia, ALL, Biological, apoptosis, Therapies, Biological Processes, enzyme inhibitors, Lymphoid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Sajid Khan, PhD1, Xuan Zhang, BMBS2*, Dongwen Lv, PhD2*, Yonghan He, MD2*, Peiyi Zhang, MS2*, Xingui Liu, PhD2*, Dinesh Thummuri, PhD2*, Qi Zhang, PhD3*, Marina Y. Konopleva, MD, PhD4, Robert A. Hromas, MD5, Guangrong Zheng2* and Daohong Zhou, MD1

637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Program: Oral and Poster Abstracts Type: Poster
Sunday, December 2, 2018: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

3086 Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II Hematology Disease Topics & Pathways: Diseases, AML, Non-Biological, Therapies, Biological Processes, chemotherapy, MDS, Technology and Procedures, DNA repair, cytogenetics, epigenetics, genetic profiling, Myeloid Malignancies, molecular testing, NGS, molecular interactions, WGS, signal transduction
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Shireen Vali, PhD1*, Taher Abbasi, MS, MBA1*, Neeraj Kumar Singh, B.Tech2*, Shahabuddin Usmani, M.Sc.2*, Deepak Anil Lala, B.Tech2*, Poornachandra G, B.Tech2*, Saumya Radhakrishnan, B.Tech2*, Shivgonda C Birajdar, MCA2*, Ganesh Naga, B.Tech2*, Leylah M. Drusbosky, PhD3 and Christopher R. Cogle, MD4

3087 Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II Hematology Disease Topics & Pathways: Biological, Diseases, Non-Biological, Therapies, Elderly, Biological Processes, chemotherapy, MDS, Technology and Procedures, enzyme inhibitors, Study Population, Clinically relevant, genomics, Myeloid Malignancies, Quality Improvement , TKI, NGS
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Lubomir Minarik, MD1,2*, Leylah M. Drusbosky, PhD3, Taher Abbasi, MS, MBA4*, Karina Vargova, MBBS, MSc5*, Vojtech Kulvait, PhD2*, Anna Jonasova, MD1*, Neeraj Kumar Singh, B.Tech6*, Yashaswini S Ullal, B.E6*, Sirisha Narayanabhatia, M.Sc.6*, Aktar Alam, BCA6*, Kunal Ghosh Roy, M.Sc.6*, Ashish Choudhary, M.Sc.6*, Shireen Vali, PhD4*, Christopher R. Cogle, MD7 and Tomas Stopka, MD, PhD1,8

3193 Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics
Program: Oral and Poster Abstracts Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Hematology Disease Topics & Pathways: Diseases, multiple myeloma, Non-Biological, Therapies, Biological Processes, chemotherapy, Technology and Procedures, DNA repair, epigenetics, Plasma Cell Disorders, cytogenetics, Lymphoid Malignancies, genomics, genetic profiling, molecular testing, NGS, molecular interactions, WGS, signal transduction
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Andrej Besse, M.Sc1*, Christopher R. Cogle, MD2, Leylah M. Drusbosky, PhD3, Shireen Vali, PhD4*, Taher Abbasi, MS, MBA4*, Neeraj Kumar Singh, B.Tech5*, Neha G Gupta, M.Sc.5*, Abha Kushwaha, M.Sc.5*, Pallavi Kumari, M.Sc.5*, Karthik Sundara Raju, M.Sc.5*, Ganesh Naga, B.Tech5*, Sayani Basu, M.Tech5*, Christoph Driessen, MD1 and Lenka Besse, PhD1*

4694 Pilot Results from an Integrated Pediatric Pulmonary Clinic on Outcomes in Children with Sickle Cell Disease
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster III Hematology Disease Topics & Pathways: Diseases, Anemias, sickle cell disease, Therapies, Non-Biological, Hemoglobinopathies, Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Vandy Black, MD, MSc1, Dima Ezmigna, MBBS1* and Laurie Duckworth, PhD, ARNP2*

3576 Long-Term Stability of the Adult Sickle Cell Quality of Life Measure (ASCQ-Me)
Program: Oral and Poster Abstracts Session: 903. Outcomes Research—Non-Malignant Hematology: Poster II Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, Hemoglobinopathies, Study Population, Clinically relevant, Quality Improvement
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Keesha L. Roach, PhD, RN1, Yingwei Yao, PhD2,3*, Marie L. Suarez, PhD3*, Veronica Angulo, BS3*, David Shuey, BS3*, Miriam O. Ezenwa, PhD, RN2*, Judith M. Schlaeger, PhD, CNM, LAc4*, Roger B. Fillingim, PhD5*, Zaijie J. Wang, PhD6*, Robert E. Molokie, MD7 and Diana J. Wilkie, PhD, RN, FAAN2,3*

2643 Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II Hematology Disease Topics & Pathways: apoptosis, AML, Diseases, Therapies, Biological Processes, DNA repair, Myeloid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Kartika Venugopal, MS*, Jianping Li, MD, Daniil E Shabashvili, PhD*, Luisa M Posada*, Yang Feng, MS*, Daphne Dupere-Richer, PhD, Aditya Bele, PhD*, Jonathan D. Licht, MD and Olga A Guryanova, MD, PhD

2742 FOXM1 Controls Leukemia Stem Cell Fate in MLL-Rearranged AML
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Yue Sheng, PhD1,2, Chao Hu, Ph.D3*, Chunjie Yu, Ph.D2,3*, Rui Ma, Master4* and Zhijian Qian, Ph.D2,3

2758 Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II Hematology Disease Topics & Pathways: AML, Diseases, Pediatric, Biological Processes, Study Population, Clinically relevant, genomics, Myeloid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Abdelrahman H Elsayed, MSc1, Huiyun Wu, PhD2*, Xueyuan Cao, PhD2*, Soheil Meshinchi, MD, PhD3, Raul Ribeiro, MD4, Jeffrey Rubnitz, MD, PhD5, Stanley Pounds, PhD2* and Jatinder K Lamba, PhD6

3509 The Association of Painful Crises with Patient Reported Outcomes in Sickle Cell Disease: The SHIP-HU Study
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster II Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Adult, Pediatric, Hemoglobinopathies, Study Population, Clinically relevant, Quality Improvement
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Donna k McClish, PhD1*, Wally R. Smith, MD2, Victoria Okhomiuna, MS, PHD2*, Daniel Sop Mouaffo, BS, MS3*, Richard Lottenberg, MD2,4, Ian Chen, MD2*, India Sisler, MD2*, Shirley Johnson, BA, LSW2*, Darla K Liles, MD5,6, Elizabeth Yang, MD, PhD7,8,9 and Thokozeni Lipato, MD10*
Monday, December 3rd

113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III
Program: Oral and Poster Abstracts Type: Poster Hematology Disease Topics & Pathways: sickle cell disease, Diseases, cellular interactions, Biological Processes, Hemoglobinopathies, erythropoiesis, Clinically relevant, genomics, inflammation, molecular interactions, pathogenesis
Monday, December 3, 2018: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
3646 Protein Phosphorylation Mechanisms Underlying Chronic Pain in Sickle Cell Disease
Program: Oral and Poster Abstracts Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Hemoglobinopathies
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Ying He, PhD1*, Diana J. Wilkie, PhD, RN, FAAN2*, Robert E. Molokie, MD3, Joseph DeSimone, PhD4* and Zaijie J. Wang, PhD5*

3752 Anti-PF4/Heparin Antibody Levels in Bacteremia, Fungemia and Sepsis
Program: Oral and Poster Abstracts Session: 311. Disorders of Platelet Number or Function: Poster III Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, HIT, Biological Processes, Clinically relevant, immune mechanism
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Satish Maharaj, MBBS1, Simone Chang, MBBS2, Karan Seegobin, MBBS1, Fauzia Rana, MD1* and Marwan Shaikh, MD1

3877 Activation of Hottip lncrna Perturbs HSC Function Leading to AML like Disease in Mice
Program: Oral and Poster Abstracts Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III Hematology Disease Topics & Pathways: Diseases, AML, Biological Processes, Technology and Procedures, epigenetics, gene editing, Myeloid Malignancies, genomics, hematopoiesis, NGS
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Huacheng Luo1*, Ganqian Zhu, PhD2, Jie Zha, MD3*, Bowen Yan, Ph. D4*, Ying Guo2*, Jianfeng Xu, PhD5*, Qian Lai1*, Bing Xu, MD, PhD6*, Feng-Chun Yang, MD, PhD2, Wei Li7*, Yi Qiu8, Mingjiang Xu, MD, PhD2 and Suming Huang1

3896 Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression
Program: Oral and Poster Abstracts Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III Hematology Disease Topics & Pathways: multiple myeloma, Diseases, smoldering myeloma, Plasma Cell Disorders, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Mahshid Rahmat, PhD1*, Nicholas Haradhvala, BA2,3*, Romanos Sklavenitis-Pistofidis, MD1*, Jihye Park, BS, DVM4, Daisy Huynh, MS1*, Mark Bustoros, MD5,6,7*, Brianna Berrios, BS1*, Mairead Reidy, PhD1*, Adriana Perilla-Glen8*, Bradley Rivotto, BS1*, Kalvis Hornburg, BA1,6,7*, David M. Dorfman, MD, PhD9, Jonathan D. Licht, MD10, Gad Getz, PhD2,3* and Irene M. Ghobrial, MD1,3,6,7

2643 Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II Hematology Disease Topics & Pathways: apoptosis, AML, Diseases, Therapies, Biological Processes, DNA repair, Myeloid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Kartika Venugopal, MS*, Jianping Li, MD, Daniil E Shabashvili, PhD*, Luisa M Posada*, Yang Feng, MS*, Daphne Dupere-Richer, PhD, Aditya Bele, PhD*, Jonathan D. Licht, MD and Olga A Guryanova, MD, PhD

3942 CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III Hematology Disease Topics & Pathways: Diseases, AML, Biological, antibodies, Therapies, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Katherine Tarlock, MD1,2, Zixing Wang3*, Rory Rohm3*, Travis Biechele4*, Rhonda E. Ries, MA5*, Tiffany Hylkema, BS5*, Jatinder K Lamba, PhD6, Gary D Means, PhD4*, Robert Thurman4*, Bill Arthur4* and Soheil Meshinchi, MD, PhD7,8

3967 Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)
Program: Oral and Poster Abstracts Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III Hematology Disease Topics & Pathways: Adult, antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Study Population, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Anthony S. Stein, MD1, Zachary F. Zimmerman2, Paul Cannell3, Hervé Dombret4, Johan Maertens, MD5*, Max S. Topp6, Janet L. Franklin7, Ze Cong, PhD, MS8*, Xinke Zhang9*, Yan Li10* and Andre C. Schuh, MD11

4015 A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Program: Oral and Poster Abstracts Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III Hematology Disease Topics & Pathways: Diseases, Leukemia, ALL, Biological, Adult, Therapies, CAR-Ts, Study Population, Lymphoid Malignancies, Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Sanfang Tu, MD & PhD1*, Lan Deng, MD&PhD1*, Rui Huang, MD & PhD1*, Xuan Zhou, MD1*, Jilong Yang, MD1*, Weijun Zhou, MD&PhD1*, Meifang Li, MD&PhD1*, Chunyan Yue, MD1*, Shaojie Wu, MD&PhD1*, Zhenling Guo1*, Lung-Ji Chang, PhD2,3,4 and Yuhua Li, MD & PhD1

4034 AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow
Program: Oral and Poster Abstracts Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III Hematology Disease Topics & Pathways: Biological, AML, Diseases, Non-Biological, Therapies, Pediatric, Biological Processes, chemotherapy, Technology and Procedures, DNA repair, Study Population, cytogenetics, epigenetics, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, molecular testing, NGS, molecular interactions, WGS, signal transduction
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Christopher R. Cogle, MD1, Taher Abbasi, MS, MBA2*, Neeraj Kumar Singh, B.Tech3*, Mohammed Sauban, B.E3*, Rahul K Raman, M.Sc.3*, Robinson Vidva, B.Tech3*, Anuj Tyagi, M.Sc.3*, Anay Ashok Talawdekar, M.Tech3*, Arko Das, M.Sc.3*, Steven M. Kornblau, MD4, Fieke W Hoff, BSc5*, Terzah M. Horton, MD, PhD6 and Shireen Vali, PhD2*

2234 Pain Management in Hemophilia Α: Analysis of a Large US Insurance Claims Database
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster I
Hematology Disease Topics & Pathways: Diseases, Hemophilia, Bleeding and clotting, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Mahek Garg1,2*, Karina Raimundo1*, Anisha Patel1* and Richard H Ko1

4731 Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the ConnectÂ® MDS/AML Disease Registry
Program: Oral and Poster Abstracts Session: 902. Health Services Research—Malignant Diseases: Poster III Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, Non-Biological, chemotherapy, MDS, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Christopher R. Cogle, MD1, Guillermo Garcia-Manero, MD2, David L. Grinblatt3, Rami S. Komrokji, MD4, Michael R. Savona, MD5, Bart L. Scott, MD6, Mikkael A. Sekeres, MD, MS7, Chrystal U. Louis8*, E. Dawn Flick9*, Melissa Nifenecker8*, Pavel Kiselev8*, Arlene S. Swern8* and David P. Steensma10

4736 Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the ConnectÂ® MDS/AML Disease Registry
Program: Oral and Poster Abstracts Session: 902. Health Services Research—Malignant Diseases: Poster III Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, Myeloid Malignancies, transfusion
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Sudipto Mukherjee, MD, PhD, MPH1, Mehrdad Abedi, MD2, Harry P. Erba, MD, PhD3, Daniel A Pollyea, MD4, Gail J. Roboz, MD5, Michael A. Thompson, MD, PhD, FASCO6, Chrystal U. Louis7*, E. Dawn Flick8*, Melissa Nifenecker7*, Pavel Kiselev7*, Arlene S. Swern7* and Christopher R. Cogle, MD9

4694 Pilot Results from an Integrated Pediatric Pulmonary Clinic on Outcomes in Children with Sickle Cell Disease
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster III Hematology Disease Topics & Pathways: Diseases, Anemias, sickle cell disease, Therapies, Non-Biological, Hemoglobinopathies, Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Vandy Black, MD, MSc1, Dima Ezmigna, MBBS1* and Laurie Duckworth, PhD, ARNP2*

1364 ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin
Program: Oral and Poster Abstracts Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I Hematology Disease Topics & Pathways: Diseases, AML, Therapies, Non-Biological, chemotherapy, Pediatric, Study Population, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)
Roya Rafiee, PhD1,2, Soheil Meshinchi, MD, PhD3 and Jatinder K Lamba, PhD4

2758 Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II Hematology Disease Topics & Pathways: AML, Diseases, Pediatric, Biological Processes, Study Population, Clinically relevant, genomics, Myeloid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Abdelrahman H Elsayed, MSc1, Huiyun Wu, PhD2*, Xueyuan Cao, PhD2*, Soheil Meshinchi, MD, PhD3, Raul Ribeiro, MD4, Jeffrey Rubnitz, MD, PhD5, Stanley Pounds, PhD2* and Jatinder K Lamba, PhD6

3646 Protein Phosphorylation Mechanisms Underlying Chronic Pain in Sickle Cell Disease
Program: Oral and Poster Abstracts Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Hemoglobinopathies
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Ying He, PhD1*, Diana J. Wilkie, PhD, RN, FAAN2*, Robert E. Molokie, MD3, Joseph DeSimone, PhD4* and Zaijie J. Wang, PhD5*

2234 Pain Management in Hemophilia Α: Analysis of a Large US Insurance Claims Database
Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster I
Hematology Disease Topics & Pathways: Diseases, Hemophilia, Bleeding and clotting, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Mahek Garg1,2*, Karina Raimundo1*, Anisha Patel1* and Richard H Ko1

4694 Pilot Results from an Integrated Pediatric Pulmonary Clinic on Outcomes in Children with Sickle Cell Disease Program: Oral and Poster Abstracts Session: 901. Health Services Research—Non-Malignant Conditions: Poster III Hematology Disease Topics & Pathways: Diseases, Anemias, sickle cell disease, Therapies, Non-Biological, Hemoglobinopathies, Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Vandy Black, MD, MSc1, Dima Ezmigna, MBBS1* and Laurie Duckworth, PhD, ARNP2*

Monthly HAAs

Honors, Awards + Achievements

Back to Issue Home

November 2018

Publications & ASH Poster Presenters

Recent Selected Publications

UF-Affiliated Posters at ASH 2018

Categories

Read This Next

Monthly HAAs

Back to Issue Home

Recent Selected Publications

UF-Affiliated Posters at ASH 2018

Share

Categories

Read This Next

Monthly HAAs

Back to Issue Home